PA8521901A1 - Derivados de 2h-tetrazol-5-il- amida - Google Patents

Derivados de 2h-tetrazol-5-il- amida

Info

Publication number
PA8521901A1
PA8521901A1 PA20018521901A PA8521901A PA8521901A1 PA 8521901 A1 PA8521901 A1 PA 8521901A1 PA 20018521901 A PA20018521901 A PA 20018521901A PA 8521901 A PA8521901 A PA 8521901A PA 8521901 A1 PA8521901 A1 PA 8521901A1
Authority
PA
Panama
Prior art keywords
rent
hydrogen
amida
tetrazol
derivatives
Prior art date
Application number
PA20018521901A
Other languages
English (en)
Inventor
Synese Jolidon
Vincent Mutel
Eric Vieira
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8521901A1 publication Critical patent/PA8521901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

EL PRESENTE INVENTO SE REFIERE A DERIVADOS DE 2H-TETRAZOL-5-IL-AMIDA DE LA FORMULA GENERAL EN DONDE R1 SIGNIFICA HIDROGENO, ALQUILO INFERIOR, -(CH2)n-CF3, (CH2)n-CHF2,-(CH2)n-CICLOALQUILO,(CH2)n-O-ALQUILO INFERIOR,-(CH2)n-O-CICLOALQUILO O- (CH2)n-C(O)O-ALQUILO INFERIOR; R2 SIGNIFICA HIDROGENO, ALQUILO INFERIOR, ALCOXI INFERIOR, HALOGENO,-C(O)-ALQUILO INFERIOR,-C(O)OH,-C(O)-ALQUILO INFERIOR,-NR3R4 O -C(O)-NR3R4 Y EN DONDE R3 Y R4 PUEDEN SER INDEPENDIENTEMENTE UNO DE OTRO HIDROGENO O ALQUILO INFERIOR; X SIGNIFICA -O-, -S-,-CH2, -OCH2- O DOS ATOMOS DE HIDROGENO QUE NO FORMAN UN PUENTE; Y N SIGNIFICA 0,1,2,3,ó 4; ASI COMO SUS SALES FARMACEUTICAMENTE ACEPTABLES. SE HA ENCONTRADO QUE LOS COMPUESTOS DE LA FORMULA GENERAL 1 SON AGONISTAS RECEPTORES DE GLUTAMATO METABOTROPICO DEL GRUPO 1 (MGLUR) Y SON UTILES POR LO TANTO EN EL TRATAMIENTO DE TRASTORNOS DEL SNC CORRESPONDIENTES.
PA20018521901A 2000-07-13 2001-07-10 Derivados de 2h-tetrazol-5-il- amida PA8521901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00115170 2000-07-13

Publications (1)

Publication Number Publication Date
PA8521901A1 true PA8521901A1 (es) 2002-04-25

Family

ID=8169240

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20018521901A PA8521901A1 (es) 2000-07-13 2001-07-10 Derivados de 2h-tetrazol-5-il- amida

Country Status (19)

Country Link
US (1) US6399641B1 (es)
EP (1) EP1303499B1 (es)
JP (1) JP3971298B2 (es)
KR (1) KR100504292B1 (es)
CN (1) CN1214017C (es)
AR (1) AR029706A1 (es)
AT (1) ATE332895T1 (es)
AU (2) AU7847201A (es)
BR (1) BR0112465A (es)
CA (1) CA2415673A1 (es)
DE (1) DE60121447T2 (es)
DK (1) DK1303499T3 (es)
ES (1) ES2267797T3 (es)
MX (1) MXPA03000221A (es)
PA (1) PA8521901A1 (es)
PE (1) PE20020409A1 (es)
PT (1) PT1303499E (es)
WO (1) WO2002006254A1 (es)
ZA (1) ZA200210157B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ545747A (en) 2003-08-06 2010-06-25 Senomyx Inc T1R hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
WO2005085214A1 (ja) * 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd ジアリール置換複素５員環誘導体
CA2597134C (en) 2005-02-04 2015-05-26 Senomyx, Inc. Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
AR055329A1 (es) 2005-06-15 2007-08-15 Senomyx Inc Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
KR101387563B1 (ko) 2006-04-21 2014-04-25 세노믹스, 인코포레이티드 고효능의 조미용 향료를 포함하는 식품 조성물 및 이의 제조 방법
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2093234A1 (en) 2008-02-08 2009-08-26 Nutrinova Nutrition Specialties & Food Ingredients GmbH Oligopeptides for use as taste modulators
TWI429404B (zh) 2008-03-03 2014-03-11 Senomyx Inc 異山梨醇衍生物及彼等作為風味改良劑、促味劑及促味增強劑之用途
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1343827A (en) * 1971-06-15 1974-01-16 Science Union & Cie Acylaminotetrazoles and process for preparing them
DE4129742A1 (de) * 1991-09-06 1993-03-11 Bayer Ag Heterocyclisch substituierte chinolylmethoxy-phenylacetamide
GB9626151D0 (en) * 1996-12-17 1997-02-05 Lilly Industries Ltd Pharmaceutical compounds
CA2313236A1 (en) * 1997-12-10 1999-06-17 Nps Pharmaceuticals, Inc. Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides, corresponding acids, and uses
US6548522B1 (en) * 1999-10-12 2003-04-15 Hoffmann-La Roche Inc. Method for treating conditions related to the glutamate receptor using carboxylic acid amide derivatives

Also Published As

Publication number Publication date
PT1303499E (pt) 2006-11-30
ES2267797T3 (es) 2007-03-16
CN1441791A (zh) 2003-09-10
AU7847201A (en) 2002-01-30
EP1303499B1 (en) 2006-07-12
PE20020409A1 (es) 2002-05-21
KR100504292B1 (ko) 2005-07-28
BR0112465A (pt) 2003-07-22
DE60121447T2 (de) 2007-02-01
JP2004504308A (ja) 2004-02-12
US20020022648A1 (en) 2002-02-21
US6399641B1 (en) 2002-06-04
CA2415673A1 (en) 2002-01-24
MXPA03000221A (es) 2003-06-06
ZA200210157B (en) 2004-03-15
AR029706A1 (es) 2003-07-10
DE60121447D1 (de) 2006-08-24
ATE332895T1 (de) 2006-08-15
EP1303499A1 (en) 2003-04-23
JP3971298B2 (ja) 2007-09-05
DK1303499T3 (da) 2006-10-30
AU2001278472B2 (en) 2006-08-03
WO2002006254A1 (en) 2002-01-24
KR20030016390A (ko) 2003-02-26
CN1214017C (zh) 2005-08-10

Similar Documents

Publication Publication Date Title
PA8521901A1 (es) Derivados de 2h-tetrazol-5-il- amida
HUP0300205A2 (en) Aurora 2 kinase inhibitor quinazoline derivatives, preparation and use thereof
GT200200073A (es) Derivados de dihidro-benzo (b) (1,4) diazepin-2-ona
TW369526B (en) Diazabicyclic neurokinin antagonists
GT200200072A (es) Derivados de dihidro-benzo (b) (1,4)-diazepin-2-ona
CY1105907T1 (el) Νεα παραγωγα της 1,2,4 - θειαδιαζολης ως ρυθμιστες υποδοχεως μελανοκορτινης
GEP20094736B (en) Prodrugs of piperazine and substituted piperidine antiviral agents
UY29927A1 (es) Derivados sustituidos de la 5-fenil-2-tioxo-imidazolin-4-ona y de la 5-fenil-2-amino-imidazolidin-4-ona y sus sales, composiciones y aplicaciones
GR3025926T3 (en) Condensed pyrimidine derivatives and their use as angiotensine II antagonists
AR040349A1 (es) Quinolinas sustituidas como antagonistas del receptor ccr5
PA8784201A1 (es) Derivado de 17b-ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene
UY26812A1 (es) Derivados de 1-sulfonil-pirrolidina
CY1109729T1 (el) Τερφαινυλ παραγωγα για θεραπεια της νοσου του alzheimer
MX2010000658A (es) Derivados de pirimidina 934.
NZ334548A (en) Azinyloxy, and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use as mixed eta/etb endothelin receptor antagonists
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
ES2160106T3 (es) Derivados de la quinazolina.
PE20001583A1 (es) Derivados de la 1-arenosulfonil-2-arilo-pirrolidina y de la piperidina
AR024746A1 (es) Androgenos oralmente activos.
PE20040757A1 (es) Derivados de benzoxazina
AR065904A1 (es) Heterociclos como antagonistas de orexina
ES2150684T3 (es) Derivados de piperazina y su utilizacion como antagonistas 5-ht1a.
MXPA05009988A (es) Derivados de 6-sulfonamida quinolina y cromeno como antagonistas de los receptores de androgenos.
ES2142397T3 (es) Derivado de morfolina.
PE20010649A1 (es) Derivados de antranilamida de piperidinas 1,4-di-sustituidas como antagonistas muscarinicos